Spots Global Cancer Trial Database for First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
Official Title: Phase I/IIa First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
Study ID: NCT04335253
Conditions
Interventions
Study Description
Brief Summary: IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.
Detailed Description: Multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers. The study will consist in a dose-escalation phase to determine the MTD, the RP2D, and the safety of EOS884448 in participants with advanced cancers.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GZA Ziekenhuizen campus Sint-Augustinus, Antwerp, , Belgium
Institut Jules Bordet, Brussels, , Belgium
Cliniques universitaires St Luc-UCL, Brussels, , Belgium
Universitair Ziekenhuis Gent, Gent, , Belgium
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
